We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+49.88%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$1.03B
AUM Growth
+$316M
Cap. Flow
+$4.54M
Cap. Flow %
0.44%
Top 10 Hldgs %
93.6%
Holding
27
New
2
Increased
4
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$52.2M
2
PBYI icon
Puma Biotechnology
PBYI
+$5.85M
3
ANAB icon
AnaptysBio
ANAB
+$4.35M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$3.75M
5
CHRS icon
Coherus Oncology
CHRS
+$3.39M

Top Sells

Rank Stock Value
1
RLMD icon
Relmada Therapeutics
RLMD
+$33.8M
2
EOLS icon
Evolus
EOLS
+$13.7M
3
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$4.21M
4
TECX
Tectonic Therapeutic
TECX
+$3.43M
5
RDUS
Radius Health, Inc.
RDUS
+$2.49M

Sector Composition

Rank Sector Weight
1 Healthcare 99.31%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ODT
1
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$596M 57.94%
14,075,269
– –
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$71.7M 6.97%
+980,461
New +$52.2M
RCKT icon
3
Rocket Pharmaceuticals
RCKT
$348M
$62.1M 6.03%
2,965,485
– –
ANAB icon
4
AnaptysBio
ANAB
$1.6B
$56.5M 5.49%
2,528,678
+237,851
+10% +$4.35M
HRTX icon
5
Heron Therapeutics
HRTX
$86.3M
$42.6M 4.14%
2,896,904
– –
LJPC
6
DELISTED
La Jolla Pharmaceutical Company
LJPC
$37M 3.6%
8,695,474
+615,129
+8% +$3.75M
BIO icon
7
Bio-Rad Laboratories Class A
BIO
$8.42B
$36.1M 3.51%
80,000
– –
UTHR icon
8
United Therapeutics
UTHR
$26.3B
$24.2M 2.35%
200,000
-8,415
-4% -$947K
RLMD icon
9
Relmada Therapeutics
RLMD
$544M
$22.4M 2.18%
500,000
-800,000
-62% -$33.8M
PBYI icon
10
Puma Biotechnology
PBYI
$406M
$14.2M 1.38%
1,365,376
+565,376
+71% +$5.85M
SGMO
11
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$14.1M 1.38%
1,578,795
-454,185
-22% -$4.21M
TECX
12
Tectonic Therapeutic
TECX
$573M
$14M 1.36%
66,667
-16,666
-20% -$3.43M
EGRX
13
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$12.3M 1.19%
255,616
– –
CHRS icon
14
Coherus Oncology
CHRS
$217M
$9.82M 0.96%
550,000
+200,000
+57% +$3.39M
LSACU
15
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
$5.5M 0.53%
500,000
– –
PRTA icon
16
Prothena Corp
PRTA
$458M
$2.86M 0.28%
273,823
-150,000
-35% -$1.67M
CTMX icon
17
CytomX Therapeutics
CTMX
$705M
$2.5M 0.24%
300,000
– –
VNDA icon
18
Vanda Pharmaceuticals
VNDA
$312M
$2.19M 0.21%
191,426
-108,374
-36% -$1.23M
RDUS
19
DELISTED
Radius Health, Inc.
RDUS
$1.62M 0.16%
119,005
-180,995
-60% -$2.49M
NCNA
20
NuCana
NCNA
$5.37M
$541K 0.05%
20
– –
TENX icon
21
Tenax Therapeutics
TENX
$385M
$416K 0.04%
+288
New +$424K
ENTA icon
22
Enanta Pharmaceuticals
ENTA
$372M
– –
-13,483
Closed -$693K
EOLS icon
23
Evolus
EOLS
$394M
– –
-3,295,000
Closed -$13.7M
UPS icon
24
United Parcel Service
UPS
$97.6B
– –
-1,000
Closed -$93K
CMRX
25
DELISTED
Chimerix, Inc.
CMRX
– –
-431,273
Closed -$621K
1
2

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $1.98B AUM 1.62% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return

Tang Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Tang Capital Management held 27 positions worth $1.03B, up 44% from $712M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Tang Capital Management's Q2 2020 filing shows 2 new, 4 increased, 7 reduced and 6 closed positions. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 980,461 shares worth $71.7M. The largest sale was Relmada Therapeutics, an estimated $33.8M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials.

  • Tang Capital Management's largest Q2 2020 buy was Biohaven Pharmaceutical Holding Company Ltd.: 980,461 shares worth $71.7M.
  • Tang Capital Management added most to Puma Biotechnology in Q2 2020, an estimated $5.85M increase.
  • Tang Capital Management's biggest Q2 2020 reduction was Relmada Therapeutics, cutting an estimated $33.8M.
  • Tang Capital Management fully exited Evolus in Q2 2020, selling an estimated $13.7M.
  • Tang Capital Management's ten largest holdings make up 94% of its $1.03B portfolio in Q2 2020.
  • Tang Capital Management opened 2 new positions and closed 6 in Q2 2020.
  • Tang Capital Management's portfolio value rose 44% quarter-over-quarter to $1.03B.

Based on Tang Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.